Table 2 Summary of the pooled HR
Studies (N) | HR (95%CI) | I 2 | P value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OS | PFS | OS without CC3 | PFS without CC3 | OS | PFS | OS withoutCC3 | PFS withoutCC3 | OS | PFS | OS withoutCC3 | PFS withoutCC3 | ||
HIPEC group vs non-HIPEC group | 13 | 0.54 (0.45-0.66) | 0.45(0.32-0.62) | 0.51(0.42-0.63) | 0.41(0.32-0.52) | 48% | 60% | 39% | 10% | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
Subgroup | |||||||||||||
Primary ovarian cancer | 6 | 0.59(0.46-0.75) | 0.41(0.32-0.54) | _ | _ | 34% | 32% | _ | _ | <0.0001 | <0.0001 | _ | _ |
Recurrent ovarian cancer | 5 | 0.45(0.24 to 0.83) | 0.55(0.27 to 1.11) | 0.38(0.25 to 0.56) | 0.41(0.27 to 0.62) | 60% | 77% | 0 | 0 | 0.01 | 0.09 | <0.0001 | <0.0001 |
Stage III-IV | 5 | 0.64(0.50 to 0.82) | 0.36(0.20 to 0.65) | _ | _ | 0 | 66% | - | - | 0.0004 | 0.0007 | - | - |
Interval CRS plus HIPEC | 2 | 0.61(0.45 to 0.83) | 0.29(0.1 to 0.86) | - | - | 50% | 80% | - | - | 0.002 | 0.03 | - | - |
Primary CRS plus HIPEC | 10 | 0.47(0.37 to 0.61) | 0.52(0.41 to 0.65) | 0.43(0.33 to 0.55) | 0.43(0.33 to 0.55) | 50% | 50% | 28% | 0 | <0.0001 | <0.0001 | <0.0001 | <0.0001 |